HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection.
Jade GhosnLambert AssoumouCaroline Lascoux-CombeGilles PeytavinKarine AmatAudrey GabassiMinh P LeRobert NzalakandaNadia ValinRoland LandmanMarie-Laure ChaixConstance DelaugerrePublished in: The Journal of infectious diseases (2021)
We compared the proportion of participants achieving of a first undetectable HIV-1-RNA (VL) in seminal plasma (SP) and in blood plasma (BP) of 19 men starting a dolutegravir (DTG)-based-regimen at the time of primary HIV infection (PHI). At baseline, median VL was 6.5 (IQR:5.6-7.9) and 4.5 (IQR:3.5-5.0) log10cp/ml in BP and SP, respectively. Between baseline and W48, a significantly higher proportion of participants achieved a first VL below LOQ in SP (93.0%) than in BP (84.2%; p=0.008). Time to first undetectable VL was 8 weeks in SP (95% CI: 5.6-10.4) and 24 weeks in BP (95% CI: 14.1-33.9).